Dornase alfa and rate of lung function decline in European patients with cystic fibrosis: A retrospective registry cohort study.
暂无分享，去创建一个
[1] R. Keogh,et al. Investigating the effects of long-term dornase alfa use on lung function using registry data. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[2] W. Morgan,et al. Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in cystic fibrosis , 2011, Pediatric pulmonology.
[3] B. Strandvik,et al. Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis , 2003, Pediatric pulmonology.
[4] H. Fuchs,et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.